Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence

Innate Immunity

Volumn 18, Issue 5, 2012, Pages 700-708

  Soares, João Bruno ^a,b   Pimentel Nunes, Pedro ^a,c   Afonso, Luís ^c   Rolanda, Carla ^b,d   Lopes, Paula ^c   Roncon Albuquerque, Roberto ^a   Gonçalves, Nádia ^a   Boal Carvalho, Inês ^a   Pardal, Fernando ^b   Lopes, Susana ^e   MacEdo, Guilherme ^e   Lara Santos, Lúcio ^c   Henrique, Rui ^c,f   Moreira Dias, Luís ^b   Gonçalves, Raquel ^b   Dinis Ribeiro, Mário ^c,g   Leite Moreira, Adelino F ^a  

^a University of Porto   (Portugal)

^b Braga Hospital   (Portugal)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d UNIVERSITY OF MINHO   (Portugal)

^e HOSPITAL DE SÃO JOÃO   (Portugal)

^f Institute of Histology and Embryology   (Portugal)

^g UNIVERSITY OF PORTO   (Portugal)

Author keywords

Chronic hepatitis; cirrhosis; hepatocarcinoma; TLR2; TLR4

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS HEPATITIS;

ADULT; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS B; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; UP-REGULATION;

EID: 84866426570     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425912436762     Document Type: Article

References (33)

1. Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology. 2007 ; 46: 590-597
2. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology. 2008 ; 48: 322-335
3. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut. 2009 ; 58: 704-720
4. Pimentel-Nunes P, Soares JB, Roncon-Albuquerque R, et al. Toll-like receptors as therapeutic targets in gastrointestinal diseases. Expert Opin Ther Targets. 2010 ; 14: 347-368
5. Soares J-B, Pimentel-Nunes P, Roncon-Albuquerque R, Leite-Moreira A. The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatology Int. 2010 ; 4: 659-672
6. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006 ; 124: 783-801
7. Beutler BA. TLRs and innate immunity. Blood. 2009 ; 113: 1399-1407
8. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol. 2002 ; 168: 554-561
9. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull. 2005 ; 28: 886-892
10. Gratz SW, Mykkanen H, El-Nezami HS. Probiotics and gut health: a special focus on liver diseases. World J Gastroenterol. 2010 ; 16: 403-410
11. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005 ; 41: 422-433
12. Pimentel-Nunes P, Roncon-Albuquerque R, Goncalves N, et al. Attenuation of toll-like receptor 2-mediated innate immune response in patients with alcoholic chronic liver disease. Liver Int. 2010 ; 30: 1003-1111
13. Beutler B. Neo-ligands for innate immune receptors and the etiology of sterile inflammatory disease. Immunol Rev. 2007 ; 220: 113-128
14. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004 ; 4: 499-511
15. Fukata M, Chen A, Klepper A, et al. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology. 2006 ; 131: 862-877
16. Chang YJ, Wu MS, Lin JT, Chen CC. Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol. 2005 ; 175: 8242-8252
17. Spitzer JA, Zheng M, Kolls JK, et al. Ethanol and LPS modulate NF-kappaB activation, inducible NO synthase and COX-2 gene expression in rat liver cells in vivo. Front Biosci. 2002 ; 7: a99 - a108
18. Lee IT, Lee CW, Tung WH, et al. Cooperation of TLR2 with MyD88, PI3K, and Rac1 in lipoteichoic acid-induced cPLA2/COX-2-dependent airway inflammatory responses. Am J Pathol. 2010 ; 176: 1671-1684
19. Guo J, Loke J, Zheng F, et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology. 2009 ; 49: 960-968
20. Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology. 2007 ; 46: 297-306
21. Li Y, Chang M, Abar O, et al. Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol. 2009 ; 51: 750-757
22. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007 ; 13: 1324-1332
23. Machida K, Tsukamoto H, Mkrtchyan H, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci USA. 2009 ; 106: 1548-1553
24. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001 ; 35: 421-430
25. Huang YH, Chou MH, Du YY, et al. Expression of toll-like receptors and type 1 interferon specific protein MxA in biliary atresia. Lab Invest. 2007 ; 87: 66-74
26. Manigold T, Bocker U, Hanck C, et al. Differential expression of toll-like receptors 2 and 4 in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2003 ; 15: 275-282
27. Starkel P, De Saeger C, Strain AJ, et al. NFkappaB, cytokines, TLR 3 and 7 expression in human end-stage HCV and alcoholic liver disease. Eur J Clin Invest. 2010 ; 40: 575-584
28. Singh R, Bullard J, Kalra M, et al. Status of bacterial colonization, Toll-like receptor expression and nuclear factor-kappa B activation in normal and diseased human livers. Clin Immunol 2010.
29. Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr. 2008 ; 138: 1452-1455
30. Pimentel-Nunes P, Afonso L, Lopes P, et al. Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res. 2011 ; 17: 677-683
31. Visvanathan K, Skinner NA, Thompson AJ, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology. 2007 ; 45: 102-110
32. Giannitrapani L, Ingrao S, Soresi M, et al. Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study. Ann N Y Acad Sci. 2009 ; 1155: 293-299
33. Martin-Sanz P, Mayoral R, Casado M, Bosca L. COX-2 in liver, from regeneration to hepatocarcinogenesis: what we have learned from animal models?. World J Gastroenterol. 2010 ; 16: 1430-1435